Objective To investigate the effect of percutaneous coronary intervention (PCI) on left ventricular remodeling and cardiac function in patients with myocardial infarction.Methods A total of 90 myocardial infarction patients in our hospital were as the research objects,a total of 45 cases underwent PCI surgery were in observation group,another 45 cases undergoing elective PCI surgery were in control group.The levels of N-terminal pro brain natriuretic peptide (NT-proBNP),norepinephrine (NE) and epinephrine (E),plasma renin (PRA),angiotensin Ⅱ (Ang Ⅱ),aldosterone (ALD) were detected before operation and on the first postoperative day.After 6 months of follow-up,the incidence of heart failure of two groups were compared.Results There was no significant difference between the two groups in preoperative NT-proBNP,NE,E,PRA,Ang Ⅱ and ALD levels (P ＞0.05),the observation group had decreased NT-proBNP,NE,E,PRA,Ang Ⅱ,ALD levels at 1 d after operation than operation before and the control group (P ＜ 0.05).At 1 month after surgery,the observation group had lower LVDEd,LVSEd,LAd,and higher LVEF than treatment before and control group (P ＜ 0.05).The incidence of heart failure after 6 months in the observation group and the control group was 1 1.1％,2 4.4 ％ respectively,and the difference was statistically significant (x2 =7.31,P ＜ 0.05).Conclusion Percutaneous coronary intervention (PCI) timing can affect the prognosis of patients with myocardial infarction.Compared with elective PCI,emergency PCI can inhibit the RAAS system and sympathetic activation,improve ventricular remodeling and left ventricular function after myocardial infarction,and reduce the incidence of secondary heart failure.

Objective To investigate the effect of percutaneous coronary intervention (PCI) on left ventricular remodeling and cardiac function in patients with myocardial infarction.Methods A total of 90 myocardial infarction patients in our hospital were as the research objects,a total of 45 cases underwent PCI surgery were in observation group,another 45 cases undergoing elective PCI surgery were in control group.The levels of N-terminal pro brain natriuretic peptide (NT-proBNP),norepinephrine (NE) and epinephrine (E),plasma renin (PRA),angiotensin Ⅱ (Ang Ⅱ),aldosterone (ALD) were detected before operation and on the first postoperative day.After 6 months of follow-up,the incidence of heart failure of two groups were compared.Results There was no significant difference between the two groups in preoperative NT-proBNP,NE,E,PRA,Ang Ⅱ and ALD levels (P ＞0.05),the observation group had decreased NT-proBNP,NE,E,PRA,Ang Ⅱ,ALD levels at 1 d after operation than operation before and the control group (P ＜ 0.05).At 1 month after surgery,the observation group had lower LVDEd,LVSEd,LAd,and higher LVEF than treatment before and control group (P ＜ 0.05).The incidence of heart failure after 6 months in the observation group and the control group was 1 1.1％,2 4.4 ％ respectively,and the difference was statistically significant (x2 =7.31,P ＜ 0.05).Conclusion Percutaneous coronary intervention (PCI) timing can affect the prognosis of patients with myocardial infarction.Compared with elective PCI,emergency PCI can inhibit the RAAS system and sympathetic activation,improve ventricular remodeling and left ventricular function after myocardial infarction,and reduce the incidence of secondary heart failure.

Objective:To investigate the effect of different P2Y12 inhibitors on the long-term prognosis of patients with diabetes mellitus (DM) and acute coronary syndrome (ACS), with or without the CYP2C19 loss-of-function (LOF) gene. Method:266 consecutive ACS patients undergoing percutaneous coronary intervention (PCI) were enrolled. According to the CYP2C19 LOF genotype, the patients were divided into rapid metabolizing-type (without the CYP2C19 LOF gene) and moderate-slow metabolizing type (with the CYP2C19 LOF gene). Each type was divided into the A group (with diabetes) and the B group (without diabetes). Each group was divided into the ticagrelor subgroup and the clopidogrel subgroup according to the type of P2Y12 platelet inhibitor. The MACE events were recorded for each subgroup over 3 years, and the prognostic impact of the CYP2C19 LOF genotype and the type of P2Y12 used were analyzed. Results:There were no significant differences in MACE, revascularization, stroke, heart failure rehospitalization, major bleeding, or all-cause mortality among subgroups of patients with rapid metabolizing type at 3 years after PCI (all P>0.05). In patients with moderate-slow metabolizing-type, the use of tegretol significantly reduced the probability of MACE events and cardiac revascularization (all P<0.01) and significantly reduced the reoccurrence of heart attack in patients with DM. Conclusions:In DM combined with ACS patients with rapid metabolizing type, the choice of different P2Y12 inhibitors after PCI had no significant effect on their prognosis. In DM combined with ACS patients with moderate-slow metabolizing type, tegretol not only significantly reduced the incidence of MACE, revascularization, and reinfarction, but also did not increase the risk of major bleeding. In terms of reducing the reoccurrence of heart attack, the benefit of using tegretol in the DM patients was greater than in the non-DM patients.

Objective:To explore the relationship between the selection of different P2Y 12 inhibitors and the long-term prognosis of acute coronary syndrome (ACS) patients with and without CYP2C19 defect gene. Method:289 consecutive ACS patients who underwent percutaneous coronary intervention (PCI) at Tianjin Third Central Hospital from March 2016 to October 2016 were selected for CYP2C19 gene polymorphism detection. According to the detection results, the patients were divided into group A (with CYP2C19 loss-of-function gene, 199 cases) and group B (without CYP2C19 loss-of-function gene, 90 cases). After PCI, different P2Y 12 inhibitors were selected. The patients were followed up for 3 years, and 23 cases were lost to follow-up. Finally, 182 cases were enrolled in group A and 84 cases were enrolled in group B. According to whether there were major adverse cardiovascular events (MACE) within 3 years, the patients in groups A and B were divided into MACE subgroups (58 cases, 32 cases) and non-MACE subgroups (124 cases, 52 cases). The single factor analysis of the two subgroups in groups A and B was carried out based on the patient's clinical data, coronary artery disease and intervention status, and postoperative drug treatment plan. Risk factors with statistical significance ( P<0.05) were selected, and multivariate logistic regression analysis was performed on groups A and B to compare the effects of different P2Y 12 inhibitors on the prognosis of the two groups. Results:The differences in platelet volume, fasting blood glucose, HbA1c, left ventricular end-diastolic diameter, proportion of single-branch lesions, proportion of intervention for left main lesions, and dual antiplatelet therapy were statistically significant between the two subgroups in group A (all P<0.05). The differences in low-density lipoprotein (LDL), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter, proportion of two-branch lesions, proportion of three-branch lesions, and proportion of using tirofeben were statistically significant between the two subgroups in group B (all P<0.05). In the group A, the choice of different P2Y 12 inhibitors was the independent risk factor for the long-term prognosis. Compared with patients treated with Ticagrelor, the probability of long-term MACE was 11.971 times larger ( OR=12.971, 95% CI: 5.028~33.464, P<0.001) among patients treated with Clopidogrel 75 mg/day, and 5.029 times larger ( OR=6.029, 95%CI: 2.278~15.958) among patients treated with Clopidogrel 100 mg/day. No significant correlation was witnessed between different P2Y 12 inhibitors and long-term prognosis in group B. In the group B, different P2Y 12 inhibitors have no significant correlation with their long-term prognosis of patients( P>0.05). Conclusions:For ACS patients with CYP2C19 loss-of-function gene, the choice of P2Y 12 inhibitors is associated with their long-term MACE events after PCI. Ticagrelor therapy brings the lowest risk of long-term MACE. For those without CYP2C19 loss-of-function gene, the correlation between the choice of different P2Y 12 inhibitors and their prognosis is not significant.